200 related articles for article (PubMed ID: 10071302)
1. RAS and leukemia: from basic mechanisms to gene-directed therapy.
Beaupre DM; Kurzrock R
J Clin Oncol; 1999 Mar; 17(3):1071-9. PubMed ID: 10071302
[TBL] [Abstract][Full Text] [Related]
2. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
Crul M; de Klerk GJ; Beijnen JH; Schellens JH
Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863
[TBL] [Abstract][Full Text] [Related]
3. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
Nammi S; Lodagala DS
Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
[TBL] [Abstract][Full Text] [Related]
4. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
Gibbs JB; Oliff A
Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitors and anti-Ras therapy.
Gibbs JB; Kohl NE; Koblan KS; Omer CA; Sepp-Lorenzino L; Rosen N; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A
Breast Cancer Res Treat; 1996; 38(1):75-83. PubMed ID: 8825125
[TBL] [Abstract][Full Text] [Related]
6. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
Helbig G; HoĊowiecki J
Wiad Lek; 2004; 57(9-10):462-7. PubMed ID: 15765763
[TBL] [Abstract][Full Text] [Related]
7. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase inhibitors versus Ras inhibitors.
Gibbs JB; Graham SL; Hartman GD; Koblan KS; Kohl NE; Omer CA; Oliff A
Curr Opin Chem Biol; 1997 Aug; 1(2):197-203. PubMed ID: 9667853
[TBL] [Abstract][Full Text] [Related]
9. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
[TBL] [Abstract][Full Text] [Related]
10. Protein farnesyltransferase inhibitors.
Ayral-Kaloustian S; Salaski EJ
Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
[TBL] [Abstract][Full Text] [Related]
11. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Rowinsky EK; Windle JJ; Von Hoff DD
J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of the ras oncogene as therapeutic targets.
Ghobrial IM; Adjei AA
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase as a target for anticancer drug design.
Qian Y; Sebti SM; Hamilton AD
Biopolymers; 1997; 43(1):25-41. PubMed ID: 9174410
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
Morgan MA; Ganser A; Reuter CW
Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
17. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
Feldkamp MM; Lau N; Roncari L; Guha A
Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
[TBL] [Abstract][Full Text] [Related]
18. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
O'Regan RM; Khuri FR
Endocr Relat Cancer; 2004 Jun; 11(2):191-205. PubMed ID: 15163298
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
Lerner EC; Hamilton AD; Sebti SM
Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
[TBL] [Abstract][Full Text] [Related]
20. [Inhibitors of Ras farnesylation: tomorrow's anticancer agents?].
Perrin D; Halazy S; Hill B
Bull Cancer; 1997 Jun; 84(6):635-42. PubMed ID: 9295868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]